α-MT is an orally competitive TH inhibitor, which has been used clinically to treat hypertension-linked pheochromocytoma and dystonia, dyskinesia and Huntington's disease [53, 54, 69]. The gene discussed is AMT; the disease is drug-induced dyskinesia.